Framework: semiconductor-framework.md (written today; resources/semiconductor-framework.md links to it). Data: eight stock-data-analyst
passes run in parallel on 2026-09-03 (Finnhub, yfinance, SEC 6-K/8-K/10-Q, company releases; consensus
from yfinance because Finnhub's estimate endpoints are paywalled). Prices are intraday 2026-09-03.
Positions held: INTC 14 sh @ 90.10 (rule-006 cap breached, hold re-authorised 2026-09-03). Open
decision: GFS-DEEP45 fired 2026-08-28 at 44.88. VWCE already holds NVDA, TSM, ASML, AMD and MU.
None of the eight is cheap. Three are good businesses at a fair price near a cycle peak (TSM, ASML, NVDA). One is a mediocre business at a fair price (GFS). Four fail the good test, and three of those (AMD, MU, ARM) fail it on the owner's own deal-breaker: cluster selling by the CEO and other officers.
| Name | Model | Cycle | Good? (of 16) | EV / price | Verdict | Cheap begins at | Action |
|---|---|---|---|---|---|---|---|
| TSM | Foundry | Peak | 15 good | 0.95 | FAIR | $316 | REVIEW alert TSM-REVIEW316; deliberate VWCE overweight if bought |
| ASML.AS | Equipment | Late | 13 good | 0.94 | FAIR | €1,076 | REVIEW alert ASML.AS-REVIEW1076; check AFM insider register first |
| NVDA | Fabless | Peak | 13 good | 0.99 | FAIR | $182 | REVIEW alert NVDA-REVIEW182; concentration is the risk |
| GFS | Foundry | Mid | 10 not good (returns) | 0.92 | FAIR | $32 | PASS on the fired DEEP45 rung. Keep GFS-DEEP40 as the owner's rung; the framework's cheap price is lower |
| INTC | IDM turnaround | Early | 6 not good | 0.86 | EXPENSIVE | $63 | Held. No adds. Ladder and kill list in INTC_plan.json stand; INTC-REVIEW65 is the cheap gate |
| MU | Memory | Peak | 10, G6 = 0 | 0.84 | EXPENSIVE | $637 | Discard. CEO sells 40,000 sh every month; P/B 10.6x vs a historical peak of 2.5x |
| AMD | Fabless | Late | 8, G5 = 0, G6 = 0 | 0.70 | EXPENSIVE | $257 | Discard. CEO + CFO + CTO + 2 SVPs sold in 90 days; 160M-share customer warrant |
| ARM | IP | Late | 9, G1 = 0, G6 = 0 | 0.51 | EXPENSIVE | $100 | Discard. FCF after SBC negative 3 of 4 years; CEO + CFO selling |
EV / price is the framework's C7: probability-weighted value two fiscal years out at a multiple that fits the model, divided by today's price. 1.25 or more is cheap, 0.90 to 1.25 fair, below 0.90 expensive. "Cheap begins" is EV ÷ 1.25. Every scenario input is listed in section 4 so the owner can argue with it.
The May 2026 supply-chain screen (30 names, zero passes) read "late-cycle euphoria". Three months on the gauges have moved further, not back:
| Gauge | Read |
|---|---|
| Revenue vs trend | NVDA +90% (FY27E), MU revenue tripled in twelve months, TSM +40%, ASML +31%, AMD +47%. Only GFS (+7.6%) and INTC (+13% FY27E) are near trend |
| Gross margin vs own range | MU 84.6% against a ten-year range of −9% to 59%; TSM 67.7% (range 51.6-67.7); NVDA 75%; ASML 54% (top of range). All record or top decile |
| Inventory | NVDA inventory +128% in five quarters against revenue +85%, purchase commitments doubled to $279B (memory); TSM inventory days 67 → 86 in one quarter. MU and ASML inventory days falling (the two "against" reads) |
| Capex | TSM 2026 capex $60-64B (+~50%) and 2027 "even more significantly higher"; MU FY26 ~$27B and FY27 reportedly >$45B; hyperscaler 2026 capex ~$725B (+77%). INTC FY27 "significantly above" FY26 |
| P/B vs own range | MU 10.6x (never above 2.5x at any prior peak); TSM 10.6x; ASML 25x; NVDA 24x. GFS 2.06x is the only one in the bottom third of its range |
Memory pricing, the sector's most sensitive gauge, is still rising but decelerating: DRAM contract prices +95% in Q1 CY26, +58-63% in Q2, forecast +13-18% in Q3 (TrendForce). Micron's own management says "meaningful moderation in the rate of price increases" is ahead. The framework's rule stands: a name at Peak cannot be cheap on current-year numbers.
| Test | NVDA | AMD | ARM | GFS | INTC | MU | TSM | ASML |
|---|---|---|---|---|---|---|---|---|
| G1 Through-cycle cash (FCF − SBC) | 2 (FY23 trough +$1.1B) | 1 (FY23 −$0.26B) | 0 (negative FY24, FY25, FY26; 4-yr sum −$774M) | 2 (FY24 +$911M) | 0 (5-yr sum ≈ −$47B) | 1 (9-yr sum +$12B; troughs negative) | 2 (positive every year) | 2 (positive every year) |
| G2 Moat, measured | 2 | 1 (AI GPUs below company GM) | 2 (97% GM) | 1 (LTAs repriced lower in 2025) | 1 (server share 73 → 65%) | 1 (trough GM −9%; share stable) | 2 | 2 (EUV monopoly) |
| G3 Returns on capital | 2 | 1 | 2 | 0 (ROE 6-7%) | 0 | 1 (10-yr avg ~10%) | 2 (ROE ~30%) | 2 (ROE ~44%) |
| G4 Balance sheet | 2 (net cash $68B) | 2 (net cash $8.8B) | 2 (net cash $3.4B) | 2 (net cash $0.7B) | 1 (net debt ~0 only after the $20B raise) | 2 (net cash $24B) | 2 (net cash $80B) | 2 (net cash €5.6B) |
| G5 Not funding itself with shares | 2 (shares −4.5% in 5 yrs) | 0 (+35%; OpenAI warrant 160M sh at $0.01) | 1 (+4.2% since IPO; SBC 22% of revenue, no buybacks) | 2 (flat; SBC 2.9%) | 0 (+20% in 12 months) | 2 (+0.9% in 5 yrs) | 2 (flat) | 2 (−4.6%; €12B programme) |
| G6 Insiders | 1 (no buys; director and EVP sales; CEO/CFO none discretionary) | 0 (Su ~$130M + Hu + Papermaster + Norrod + Grasby) | 0 (Haas + Child + five officers) | 1 (no buys; Mubadala 85% → 73%) | 2 (CEO $10M at 95, CFO $250K at 42.50; no cluster) | 0 (Mehrotra 40,000 sh/month, ~$136M since May; Arnzen $57M; Sadana $10M) | 2 (151 Form 4 buys vs 2 sales) | 1 (foreign issuer; AFM register not checked) |
| G7 Story matches numbers | 2 | 2 | 1 (stopped disclosing Armv9 mix and RPO in 2026) | 1 (segments do not sum; Q3 guide soft) | 1 (18A in the numbers; foundry still −$2.1B/qtr) | 2 | 2 | 1 (stopped publishing quarterly bookings) |
| G8 Concentration, geopolitics | 0 (three customers 54%; China revenue gone) | 1 (China MI308 hole) | 1 (China 18%; SoftBank 87% with $18.5B margin loans) | 1 (CHIPS dependence; controlling holder selling) | 1 (US government 10% + warrant) | 1 (CXMT 10% of DRAM) | 1 (Nvidia 19% + Apple 17%; Taiwan) | 1 (China 14% and a live US push for a total ban) |
| Total | 13 | 8 | 9 | 10 | 6 | 10 | 15 | 13 |
| Good? | yes | no (G5, G6) | no (G1, G6) | no (G3) | no (G1, G5) | no (G6) | yes | yes |
Reading the zeros:
| Test | NVDA | AMD | ARM | GFS | INTC | MU | TSM | ASML |
|---|---|---|---|---|---|---|---|---|
| Price | $229.95 | $457.31 | $243.55 | $44.29 | $92.12 | $951.73 | $415.47 | €1,423.40 |
| Trailing P/E (GAAP) | 29x | 118x | 251x | 35x | loss | 21.5x | 31x | 52-56x |
| Forward P/E, next FY | 24.7x (FY27E 9.29) | 60x (FY26E 7.57 nG) | 109x (FY27E 2.23 nG) | 22.7x (FY26E 1.96 nG) | 61x (FY26E 1.51 nG) | 13.0x (FY26E 73.40) | 24.6x (FY26E 16.91) | 37.3x (FY26E €38.19) |
| Forward P/E, FY after | ~15x (FY28 indicative 15.4) | 30x (FY27E 15.45 nG) | 80x (FY28E 3.06 nG) | 16.9x (FY27E 2.62 nG) | 45x (FY27E 2.04 nG) | 6.1x (FY27E 155) | 19.0x (FY27E 21.86) | 27.5x (FY27E €51.70) |
| C1 Normalised EPS used | 7.90 (FY27E less 15%) | 4.60 (nG TTM less SBC) | 0.97 (GAAP TTM) | 1.30 (mid-cycle margin) | n/a (loss) | 10 (range 4-17; 10-yr avg 3.94) | 13.5 (5-yr median margin) | €34 (5-yr median margin) |
| C2 Break-even growth, normalised | 10.3% | 45% | 121% | 12.8% | n/a | 43% | 11.1% | 16.7% |
| C2 Break-even growth, FY-after EPS (SBC-adjusted) | 3.2% | 12.7% (13.5) | 35% | 5.8% (2.20) | 18.3% | −1.2% (on peak EPS) | 5.3% | 9.5% |
| Demonstrated growth (5-yr revenue CAGR) | 67% (use 20% as durable) | 29% (22% organic) | 22% (3-yr) | 7% | negative | 13% (10-yr) | 22% (16.5% 10-yr) | 18.5% |
| C3 Implied-growth gap (trailing vs forward) | 10 → 8 pts: small | 54 → 13: inflection priced | 121 → 35: inflection priced | 13 → 6: modest | n/a → 18 | 6.5 → −1: peak priced as permanent | 11 → 5: modest | 22 → 10: modest |
| C4 (FCF − SBC) / market cap | 2.2% | 0.9% | 0.1% | 2.3% | negative | 2.3% (TTM; 9-yr FCF total is 1.2% of today's cap) | 1.7% (capex 45% of revenue) | 1.5% |
| C5 Reverse DCF: 10-yr FCF CAGR the price needs | 23.5% | 42.5% | 88% | 22.9% | n/a | 22.8% | 29.3% | 30.9% |
| C6 P/B vs justified (capital-heavy only) | — | — | — | 2.06x vs 0.6x (today) / 1.5x (2028 target) | ~4.5x pro-forma vs negative ROE | 10.6x vs 9x only if 50% ROE persists; 1x on normalised ROE | 10.6x vs 11x at 30% ROE and 8% growth | — |
| C7 EV / price | 0.99 | 0.70 | 0.51 | 0.92 | 0.86 | 0.84 | 0.95 | 0.94 |
| Verdict | FAIR | EXPENSIVE | EXPENSIVE | FAIR | EXPENSIVE | EXPENSIVE | FAIR | FAIR |
Two readings matter more than the rest of the table:
EPS two fiscal years out (FY27 for Dec-year names, FY28 for NVDA and ARM) × multiple; probabilities bear / base / bull. SBC-adjusted where non-GAAP was the only consensus.
| Name | Bear (p) | Base (p) | Bull (p) | EV | Price | EV/price |
|---|---|---|---|---|---|---|
| NVDA | AI capex digestion 2027-28, revenue −35%: EPS 6.0 × 16 = 96 (0.30) | Capex flattens near $800B, EPS 11.0 × 20 = 220 (0.45) | 70% FY28 guide delivered, EPS 16 × 25 = 400 (0.25) | 228 | 230 | 0.99 |
| AMD | MI450 slips, OpenAI slows: EPS 8 × 20 = 160 (0.30) | EPS 13 (consensus 15.45 less SBC/amort.) × 25 = 325 (0.45) | EPS 17 × 30 = 510 (0.25) | 322 | 457 | 0.70 (0.64 after the warrant) |
| ARM | Royalty growth stalls at low teens: 2.6 × 30 = 78 (0.30) | Consensus 3.06 × 40 = 122 (0.45) | AGI CPU lands: 3.7 × 50 = 185 (0.25) | 125 | 244 | 0.51 |
| GFS | Mobile keeps falling, auto stalls: 1.4 × 15 = 21 (0.30) | 2.2 (consensus 2.62 less SBC) × 18 = 40 (0.45) | Photonics + DC + auto recovery: 3.0 × 22 = 66 (0.25) | 41 | 44 | 0.92 |
| INTC | (from INTC_thesis.md) 1.50 × 20 = 30 (0.30) | 2.75 × 30 = 83 (0.45) | 3.75 × 35 = 131 (0.25) | 79 | 92 | 0.86 |
| MU | Pricing rolls over in 2027 as Hynix, Samsung, CXMT capacity lands: 40 × 8 = 320 (0.35) | 120 × 7 = 840 (0.40) | Consensus 155 × 9 = 1,395 (0.25) | 797 | 952 | 0.84 |
| TSM | 2027 digestion, GM back to 58%: 15 × 17 = 255 (0.30) | 20 (consensus 21.86 haircut) × 20 = 400 (0.45) | 23 × 24 = 552 (0.25) | 395 | 415 | 0.95 |
| ASML | WFE digestion + MATCH Act China ban: €40 × 25 = 1,000 (0.30) | €48 × 28 = 1,344 (0.45) | €55 × 32 = 1,760 (0.25) | 1,345 | 1,423 | 0.94 |
Multiples: memory at peak earnings has historically cleared at 5-8x (MU 2018: 5.4x), hence 7-9x on FY27; foundry 17-24x; equipment 25-32x; fabless 16-30x on the cycle read. The bear probabilities are 0.30 (0.35 for MU) because every gauge in section 1 reads late or peak.
TSM. The best business here and the benchmark for the rest: 67.7% gross margin at 60% operating margin, $80B net cash, flat share count, dividend raised 17% in August, wafer prices going up 5-10% in 2027 with a further 10-15% surcharge on HPC. Insiders filed 151 purchases against two sales. Two customers are 36% of revenue, Nvidia now the largest at 19%, and both have nowhere else to go until Intel 14A or Samsung reach parity. Capex is 45% of revenue and rising, which is why FCF yield is 1.7% on a business earning 30% on equity. Fair at 415; cheap at 316, roughly where it traded in January.
ASML. The only monopoly in the set, with a backlog that funds two more years: FY26 guide raised three times to €43-45B, 2027 orders "substantially secured", capacity up 30% for 2027. China fell from 42% to 14% of system sales in four quarters, so the export-control hole is mostly behind it, except that the US is now pushing the Netherlands toward a total ban including servicing of installed tools. Net cash €5.6B, share count down 4.6%, SBC immaterial. It stopped publishing quarterly bookings in 2026, the one metric an equipment framework leans on. Insider transactions were not checked (AFM register, not SEC), which is the one gap to close before any buy. Fair at €1,423; cheap at €1,076.
NVDA. By the checklist a good business: FCF after SBC positive even in the FY23 trough, $68B net cash, share count down 4.5% in five years, a $80B buyback and a 25x dividend raise in May. By the cycle gauges the most extended name here: inventory up 128% in five quarters against revenue up 85%, purchase commitments doubled to $279B, gross margin guided down to 71-72% on HBM cost, three customers at 54% of revenue and every one of them designing its own silicon. Zero open-market insider buys; a director sold $445M. Management guided FY28 revenue +70%. On forward earnings it is the cheapest of the eight; on the cycle it cannot be called cheap. Fair at 230; cheap at 182.
GFS. Fell 52% from a May high that coincided with Mubadala's 22M-share block; then a soft Q3 guide, flat adjusted FCF in Q2 and a sector sell-off. Net cash, buyback, first dividend, no insider cluster, utilisation in the high 80s. But mobile revenue has fallen four quarters running, automotive flipped to −10% in Q2 after +24% and +30%, the LTA backlog was renegotiated lower, and ROE is 6-7%. At 44 the price is fair for what it earns; it is not the "2x trough earnings, genuine Graham margin" the June alert imagined because the E was the problem, not the P. The fired DEEP45 rung is a PASS. Cheap begins near 32.
INTC. Held. Today's data confirms yesterday's thesis line for line: 18A is in the numbers (revenue
+18%, gross margin 40%, DCAI +59%), foundry still loses $2.1B a quarter, no external 14A customer, the
company sold $20B of stock at 95 in August. CEO and CFO buying, no cluster. Six of sixteen on the good
test, expensive at 0.86. The plan stands: trim at 115, kill list in INTC_plan.json, cheap at 65.
MU. The textbook case for the framework. Trailing P/E 21x, FY27 P/E 6x, and every cycle gauge but inventory at an all-time extreme: 84.6% gross margin against a ten-year range of −9% to 59%, revenue tripled on price (DRAM bits +low single digits, ASP +60% in one quarter), P/B 10.6x where no prior peak exceeded 2.5x, capex guided from $27B to over $45B, CXMT at 10% of DRAM and shipping HBM3E. The CEO sells 40,000 shares a month. Through-cycle, nine years of FCF after SBC total $12B against a $1.07T market cap. The May note said the entry is the trough, below 2x tangible book; that is still the entry.
AMD. Revenue +47% and data centre +107%, but gross margin stuck at 54-57% because AI accelerators earn below the company average, FCF after SBC yields 0.9%, share count up 35% in five years plus a 160M-share warrant handed to OpenAI at a cent. The insider cluster is the widest of the eight. Expensive at 0.70 before the warrant, 0.64 after.
ARM. The best franchise in the set (97% gross margin, 350bn chips shipped) attached to the worst equity: FCF after SBC negative three of four years, SBC 22% of revenue, no buybacks, GAAP P/E 251x, FY28 non-GAAP P/E 80x, break-even growth of 35% forever. It cut FY27 royalty growth to "high teens" in July, stopped disclosing its two key metrics, is moving into selling its own chips against its licensees, and the CEO and CFO both sold. SoftBank holds 87% with $18.5B of margin loans against the shares.
TSM-REVIEW316 (below 316), ASML.AS-REVIEW1076 (below €1,076), NVDA-REVIEW182 (below 182).GFS-DEEP45 is PASS (not cheap, returns too low). The
triggered row and GFS-DEEP40 are left for the owner; the framework's cheap price is 32.INTC-REVIEW65 stand.INTC_plan.json kill conditions and rungs; a named 14A customer is the bull trigger.ASML insider transactions (AFM register) unchecked. GFS China revenue % not found. NVDA FY28 consensus unreliable (management's +70% revenue guide used as the bull). MU FY27 capex ">$45B" is a secondary source. Finnhub's insider feed missed the INTC CEO's August Form 4 entirely and lags a quarter on financials; yfinance P/B and yield fields are wrong for every ADR. All balance-sheet ratios above were recomputed from filings.